LY2127399 + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Trial Timeline
Jan 1, 2012 → Oct 1, 2015
NCT ID
NCT01488708About LY2127399 + Placebo
LY2127399 + Placebo is a phase 3 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01488708. Target conditions include Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Lupus Erythematosus were approved
Approved (10) Terminated (3) Active (8)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01488708 | Phase 3 | Terminated |
| NCT01202760 | Phase 3 | Completed |
| NCT00882999 | Phase 2 | Completed |
| NCT00785928 | Phase 2 | Completed |
| NCT00689728 | Phase 2 | Completed |
| NCT00308282 | Phase 2 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus